NCT07885436
68Ga-XHER2 PET/CT for HER2 Assessment
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Evaluate the feasibility of PET/CT imaging with 68Ga-XHER2 for the non-invasive assessment of HER2 expression in various cancer types.
Timeframe: 1month
Secondary (1)
Description of 68Ga-XHER2 uptake by measuring standardized uptake value (SUV) in various types of tumors
Arms and interventions
68Ga-XHER2Experimental
Each subject receives a single intravenous injection of 68Ga-XHER2 and undergoes PET/CT imaging within the specified time.
Drugs: 68Ga-XHER2 PET/CT
Sites
1 site in 1 country
- The First Affiliated Hospital of Xiamen UniversityXiamen, Fujian, China